Delving into the Latest Updates on YG-1699 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

+ [1]

Target

SGLT1 x SGLT2

Action

inhibitors

Mechanism

SGLT1 inhibitors(Sodium/glucose cotransporter 1 inhibitors), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors)

Therapeutic Areas

Cardiovascular DiseasesUrogenital DiseasesCongenital Disorders+ [3]

Active Indication

Chronic nephritisHeart FailureCystic Fibrosis

Inactive Indication

Diabetes MellitusDiabetes Mellitus, Type 1

Originator Organization

Youngene Therapeutics Co., Ltd.

Active Organization

Youngene Therapeutics Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The goal of this clinical trial is to learn PK and PD of YG1699 in patients with diabetes and renal dysfuction.
Participants will:
Take YG1699 or a placebo every day for 8 days. Visit the clinic 7 times for checkups and tests. Keep a diary of their symptoms. Estimate PK data from a single dose of YG1699. Estimate PD data at baseline and the last day.

Start Date31 Oct 2024

Sponsor / Collaborator

Shanghai Renji Hospital

NCT05089617

/ CompletedPhase 1

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Administration of YG1699 in Healthy Chinese Subjects: a Randomized, Double-blind, Placebo-controlled, Single Ascending Dose (SAD) and Multi-dose, Sequential, Bridging Study

This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multi-dose, sequential, bridging study in healthy volunteer using YG1699 .

Start Date09 Jan 2022

Sponsor / Collaborator-

CTR20212299

/ CompletedPhase 1

评价 YG1699在中国健康受试者口服给药的安全性、耐受性和药代动力学：随机、双盲、安慰剂对照、单次给药剂量递增（SAD）和多次给药、序贯、桥接研究

[Translation] To evaluate the safety, tolerability and pharmacokinetics of oral administration of YG1699 in healthy Chinese subjects: a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple dose, sequential, bridging study

主要目的：评价 YG1699单次口服给药剂量递增（SAD）和多次口服给药对中国健康受试者的安全性和耐受性。次要目的：评价 YG1699单次口服给药剂量递增（SAD）和多次口服给药在中国健康受试者的药代动力学。

[Translation]

Primary objective: To evaluate the safety and tolerability of single ascending oral dose (SAD) and multiple oral administration of YG1699 in healthy Chinese subjects. Secondary objective: To evaluate the pharmacokinetics of single ascending oral dose (SAD) and multiple oral administration of YG1699 in healthy Chinese subjects.

Start Date09 Jan 2022

Sponsor / Collaborator

Youngene Therapeutics Co., Ltd.

100 Clinical Results associated with YG-1699

Login to view more data

100 Translational Medicine associated with YG-1699

Login to view more data

100 Patents (Medical) associated with YG-1699

Login to view more data

1

Literatures (Medical) associated with YG-1699

01 Jun 2024·Clinical Pharmacology & Therapeutics

A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin

Article

Author: Urbina, Silvia ; Li, Tong ; Lapuerta, Pablo ; Hompesch, Marcus ; He, Jiaojuan ; Wittle, Alyssa ; Li, Chenghai ; Wang, Helen

YG1699 is a novel inhibitor of sodium‐glucose cotransporter 1 (SGLT1) and SGLT2. This double‐blind, 3‐way crossover trial compared YG1699 to dapagliflozin as an adjunct to insulin in people with type 1 diabetes (T1D) on insulin pump therapy. Treatment periods included four mixed meal tolerance tests (MMTTs) and insulin withdrawal tests per person. Nineteen adults with T1D were randomized to YG1699 10 mg, YG1699 25 mg, and dapagliflozin 10 mg once daily for 1 week in different orders. The primary end point was the difference in area under the curve (AUC) in plasma glucose (AUC0–120min) after an MMTT between treatment groups. Mean change in plasma glucose after an MMTT (AUC0–120min) was lower for YG1699 10 mg vs. dapagliflozin (89.51% of baseline vs. 102.13%, 90% confidence interval (CI) vs. dapagliflozin, −6% to −16%, P = 0.0003) and for YG1699 25 mg (84.83% vs. 102.13%, 90% CI vs. dapagliflozin −13% to −22%, P < 0.0001). At 120 minutes, mean glucose values on no treatment, dapagliflozin, YG1699 10 mg, and YG1699 25 mg were 149 (SE 7.6), 141 (SE 6.1), 128 (SE 6.9), and 115 (SE 7.8) mg/dL, respectively. Insulin dose requirements were lower for YG1699 10 mg and 25 mg vs. dapagliflozin for bolus insulin, and for YG1699 10 mg vs. dapagliflozin for total daily insulin. Safety profiles were similar between treatment groups. YG1699 reduced post‐prandial glucose more than dapagliflozin in people with T1D on insulin pump therapy. The results were consistent with dual SGLT1/SGLT2 inhibition by YG1699.

100 Deals associated with YG-1699

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus	Phase 2	China	Youngene Therapeutics Co., Ltd.	09 Jan 2022
Diabetes Mellitus, Type 1	Phase 2	United States	Youngene Therapeutics Co., Ltd.	17 Jun 2021
Chronic nephritis	Phase 1	United States	Youngene Therapeutics Co., Ltd.	30 Jan 2022
Heart Failure	Phase 1	United States	Youngene Therapeutics Co., Ltd.	30 Jan 2022
Cystic Fibrosis	Preclinical	United States	Youngene Therapeutics Co., Ltd.	30 Jan 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04956263 (phase 2a, EASD2022)	Phase 2	Diabetes Mellitus, Type 1 hemoglobin A1C	19	YG1699 10 mg	armncpvxlo(xhvnhuepgq) = ewdjiqjgiq npplypjkre (ohbmohbfwi ) View more	Positive	21 Sep 2022
				YG1699 25 mg	armncpvxlo(xhvnhuepgq) = zmvpomyvrt npplypjkre (ohbmohbfwi ) View more
YG1699 (EASD2021)	Not Applicable	Diabetic Nephropathies A1C \| GFR \| UACR	13	YG1699	glzvjtxgss(okfkdagkcm) = animals treated with YG1699 developed soft stools that resolved during washout qblmddmanc (fknhchanuc )	Positive	30 Sep 2021
				Vehicle